Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
Recruiting now · Phase 3
Conditions studied: Dry Eye
In brief
This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.
Key facts
- Study ID
- NCT06360133
- Run by
- VivaVision Biotech, Inc
- People needed
- 700
- Starts
- 2024-04-01
- Expected to finish
- 2026-03-31
- Last updated by the study team
- 2024-11-20
Who can join
Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Provided written informed consent prior to any study-related procedures.
- Are between 30 and 80 years of age.
- Have a history of dry eye disease in both eyes.
- Have been using artificial tears within 30 days of the screening visit
- Have an Eye dryness score ≥50 (0-100 point VAS)
- Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2: 1) total CFS (tCFS) score ≥6; 2) any subregion CS score ≥2.5; 3) Schirmer score (without anesthesia) ≥1 and ≤7 mm/5 min.
- Have a BCVA in the study eye of ≥4.3 (Standard for Logarithmic Visual Acuity Charts, 5-mark record).
You may not qualify if…
- Have a known hypersensitivity or contraindication to the IP or components of IP.
- Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.
- Woman of childbearing potential (WOCP) who are pregnant, lactating, or preparing for pregnant.
Where it is running
- Eye & Ent Hospital of Fudan University — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.